<DOC>
	<DOCNO>NCT02368522</DOCNO>
	<brief_summary>The study aim collect information current treatment pattern Hepatitis C participate country . There also focus patient receive daclatasvir-containing treatment regimen follow prospectively 12 month treatment initiation collect real-world data effectiveness safety treatment . Additional analysis differentiate select subpopulation .</brief_summary>
	<brief_title>Comparative Assessment Utilization Antiviral Therapies Hepatitis C Effectiveness Daclatasvir-containing Regimens Real-life Clinical Care Europe ( CMPASS-EU )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Adult ( â‰¥18 year inclusion ) Diagnosed chronic hepatitis C infection Whose physician already decide initiate new HCV treatment new daclatasvircontaining regimen Informed consent participate study Participation clinical trial early access program HCV therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>